北里大学 北里研究所病院は、東京都港区白金五丁目にある医療機関。学校法人北里研究所が運営する病院である。北里柴三郎によって設立された土筆ヶ丘養生園を起源とする。東京都の災害拠点病院に指定されている。

During the past decade, Kitasato University Kitasato Institute Hospital conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 14 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 12 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kitasato University Kitasato Institute Hospital" #1 sponsor was "Pfizer" with 11 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Galapagos NV" with 3 trials sponsored and "Shire" with 3 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kitasato University Kitasato Institute Hospital" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Kitasato University Kitasato Institute Hospital" are "Ulcerative Colitis" (20 trials), "Crohn's Disease" (6 trials), "Colitis, Ulcerative" (2 trials), "Migraine" (2 trials) and "Osteoarthritis, Hip" (2 trials). Many other conditions were trialed in "Kitasato University Kitasato Institute Hospital" in a lesser frequency.

Most popular intervention types in "Kitasato University Kitasato Institute Hospital" are "Drug" (32 trials), "Biological" (4 trials), "Other" (4 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Etrasimod" (4 trials), "Filgotinib" (4 trials), "Guselkumab" (4 trials) and "CP-690,550" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kitasato University Kitasato Institute Hospital" are 33 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Kitasato University Kitasato Institute Hospital". undefined are not yet recruiting, 10 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 13 completed trials in Kitasato University Kitasato Institute Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Kitasato University Kitasato Institute Hospital, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".